Skip to main content

Table 1 Characteristics of studies included in quantitative analysis

From: Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis

Disease

AIHA

MAHA

All studies

37 studies

1057 patients

24 studies

746 patients

13 studies

311 patients

 

wAIHA

8 studies

182 patients

TTP

12 studies

297 patients

CAD

5 studies

173 patients

HUS

1 study

14 patients

Comparative studies

10 studies

297:405 patients

7 studies

232:303 patients

3 studies

65:102 patients

  1. Publication year: 2004–2018; sample size: 10–86 (mean age: 50.6, mean male proportion: 41.0%); rituximab regimen: 28 with 375 mg/m2 4 weekly, 8 with other regimen (e.g. 100 mg 4 weekly); study design: 13 clinical trials, 24 observational studies; 1st evaluation time: 0.2 months–1 year; follow-up time: 6–83 months